Author: Editor

GRACE – Global Resource for Advancing Cancer Education Published on Dec 17, 2018 GRACE has partnered with Clinical Care Options (CCO) Oncology, to share with our community a series of educational videos regarding Measurable Residual Disease (MRD) in acute lymphocytic leukemia (ALL). This panel consisted of Drs. Elias Jabbour, MD, (Associate Professor Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston, Texas), Joseph D. Khoury, MD, (Professor, Department of Hematology at the University of Texas MD Anderson Cancer Center in Houston, Texas), and Aaron C. Logan, MD, PhD, (Associate Professor Division of Hematology and Blood…

GRACE – Global Resource for Advancing Cancer Education Published on Dec 17, 2018 GRACE has partnered with Clinical Care Options (CCO) Oncology, to share with our community a series of educational videos regarding Measurable Residual Disease (MRD) in acute lymphocytic leukemia (ALL). This panel consisted of Drs. Elias Jabbour, MD, (Associate Professor Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston, Texas), Joseph D. Khoury, MD, (Professor, Department of Hematology at the University of Texas MD Anderson Cancer Center in Houston, Texas), and Aaron C. Logan, MD, PhD, (Associate Professor Division of Hematology and Blood…

Luis G. Paz-Ares, MD, PHD will be presenting Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial June 1st, 2019 McCormick Place Hall D2, 3pm

GRACE – Global Resource for Advancing Cancer Education Published on Dec 17, 2018 GRACE has partnered with Clinical Care Options (CCO) Oncology, to share with our community a series of educational videos regarding Measurable Residual Disease (MRD) in acute lymphocytic leukemia (ALL). This panel consisted of Drs. Elias Jabbour, MD, (Associate Professor Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston, Texas), Joseph D. Khoury, MD, (Professor, Department of Hematology at the University of Texas MD Anderson Cancer Center in Houston, Texas), and Aaron C. Logan, MD, PhD, (Associate Professor Division of Hematology and Blood…

GRACE – Global Resource for Advancing Cancer Education Published on Dec 17, 2018 GRACE has partnered with Clinical Care Options (CCO) Oncology, to share with our community a series of educational videos regarding Measurable Residual Disease (MRD) in acute lymphocytic leukemia (ALL). This panel consisted of Drs. Elias Jabbour, MD, (Associate Professor Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston, Texas), Joseph D. Khoury, MD, (Professor, Department of Hematology at the University of Texas MD Anderson Cancer Center in Houston, Texas), and Aaron C. Logan, MD, PhD, (Associate Professor Division of Hematology and Blood…

GRACE – Global Resource for Advancing Cancer Education Published on Dec 17, 2018 GRACE has partnered with Clinical Care Options (CCO) Oncology, to share with our community a series of educational videos regarding Measurable Residual Disease (MRD) in acute lymphocytic leukemia (ALL). This panel discussion was made up of Drs. Elias Jabbour, MD, (Associate Professor Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston, Texas), Joseph D. Khoury, MD, (Professor, Department of Hematology at the University of Texas MD Anderson Cancer Center in Houston, Texas), and Aaron C. Logan, MD, PhD, (Associate Professor Division of…

GRACE – Global Resource for Advancing Cancer Education Published on Mar 26, 2019 GRACE is excited to bring to you a new series on Cancer Myths in the Latin Community. Our friend and partner, Narjust (N.J.) Duma, MD is a Chief Hematology/Medical Oncology Fellow at Mayo Clinic in Rochester, MN. Dr. Duma is committed to her research and advocacy in diversity and inclusion. She was recognized as the 2018 resident of the year by the National Hispanic Medical Association. N.J. speaks to cancer myths in the Latino community, and in this video N.J. discusses mammogram myths. See more at cancerGRACE.org.

GRACE – Global Resource for Advancing Cancer Education Published on Jun 26, 2018 Kurtis Davies, PhD, with the University of Colorado Health Sciences Center Department of Pharmacology, joined GRACE for our Webinar Series on Molecular Diagnostic Testing and Next Generation sequencing in Lung Cancer. In this video, Dr. Davies explains how targeted therapies treat cancer. Please visit our forums at http://cancergrace.org/forum/q-and-a-…, and scroll to the bottom of the page to ask a question! http://cancerGRACE.org/

GRACE – Global Resource for Advancing Cancer Education Published on Jun 26, 2018 Kurtis Davies, PhD, with the University of Colorado Health Sciences Center Department of Pharmacology, joined GRACE for our Webinar Series on Molecular Diagnostic Testing and Next Generation sequencing in Lung Cancer. In this video, Dr. Davies explains genetic testing in lung cancer. Please visit our forums at http://cancergrace.org/forum/q-and-a-…, and scroll to the bottom of the page to ask a question! http://cancerGRACE.org/

GRACE – Global Resource for Advancing Cancer Education Published on Apr 15, 2019 For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

GRACE – Global Resource for Advancing Cancer Education Published on Aug 22, 2018 Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case based scenarios. In this video, the doctors discuss a frail patient with metastatic squamous NSCLC with low tumor PD-L1 expression. They discuss what is the best treatment approach for a patient like this? For more information visit us at http://cancerGRACE.org/

GRACE – Global Resource for Advancing Cancer EducationPublished on Mar 26, 2019GRACE is excited to bring to you a new series on Cancer Myths in the Latin Community. Our friend and partner, Narjust (N.J.) Duma, MD is a Chief Hematology/Medical Oncology Fellow at Mayo Clinic in Rochester, MN. Dr. Duma is committed to her research and advocacy in diversity and inclusion. She was recognized as the 2018 resident of the year by the National Hispanic Medical Association. N.J. speaks to cancer myths in the Latino community, and in this video N.J. discusses biopsy myths. See more at cancerGRACE.org

GRACE – Global Resource for Advancing Cancer Education Published on Mar 26, 2019 GRACE is excited to bring to you a new series on Cancer Myths in the Latin Community. Our friend and partner, Narjust (N.J.) Duma, MD is a Chief Hematology/Medical Oncology Fellow at Mayo Clinic in Rochester, MN. Dr. Duma is committed to her research and advocacy in diversity and inclusion. She was recognized as the 2018 resident of the year by the National Hispanic Medical Association. N.J. speaks to cancer myths in the Latino community, and in this video N.J. discusses alternative medicine in cancer. See more…

GRACE – Global Resource for Advancing Cancer Education Published on Mar 26, 2019 GRACE is excited to bring to you a new series on Cancer Myths in the Latin Community. Our friend and partner, Narjust (N.J.) Duma, MD is a Chief Hematology/Medical Oncology Fellow at Mayo Clinic in Rochester, MN. Dr. Duma is committed to her research and advocacy in diversity and inclusion. She was recognized as the 2018 resident of the year by the National Hispanic Medical Association. N.J. speaks to cancer myths in the Latino community, and in this video N.J. discusses 3 common myths about breast cancer.…

Published on Jun 26, 2018 Kurtis Davies, PhD, with the University of Colorado Health Sciences Center Department of Pharmacology, joined GRACE for our Webinar Series on Molecular Diagnostic Testing and Next Generation sequencing in Lung Cancer. In this video, Dr. Davies explains the biology of cancer cells. Please visit our forums http://cancerGRACE.org/

The Eon Expert Series: Defying Lung Cancer with Eon + Mark Cuban Why does health tech hurt us more than help? We are asking the tough questions. Dallas, TX 5/16/2019   Join us May 20, 2019 at 9 AM CT for an online conversation with Mark Cuban, Dr. Gerard Silvestri, Dr. Peter Mazzone, and Dr. George A. Eapen. The panel will discuss real healthcare technology issues that have led to patients, health care providers and hospitals facing an ever-widening gap between what technology can do and what is currently implemented. Technology has improved processes and become less expensive in every…

Read the full transcription HERE: http://bit.ly/MarkCubanEonExpertSeries A discussion with Mark Cuban and three leading Pulmonologists regarding problems in healthcare technology and innovative solutions available.

  Philadelphia, PA (May 13, 2019) – Oncoceutics announced today that Michael Chiarella, an industry veteran with more than 20 years’ experience at a number of large and small biotech companies, is joining the company as Vice President, Clinical Operations. Mr. Chiarella will be responsible for building out Oncoceutics’ clinical operations in connection with the company’s preparation for an eventual filing of a New Drug Application (NDA) for Oncoceutics’ lead compound, ONC201.ONC201 is currently in Phase II clinical trials for a number of oncology indications, including adult recurrent H3 K27M-mutant high-grade glioma, an indication for which the company has received…

UCI team helps uncover how ‘FLASH radiotherapy’ reduces neural cell damage   Irvine, Calif., May 13, 2019 — In hopeful news for brain cancer patients, researchers from the University of California, Irvine and the University of Lausanne in Switzerland have discovered how an experimental technology called FLASH radiotherapy dramatically reduces the adverse cognitive side effects unleashed by traditional radiation treatments.   “Although more research needs to be done, this has the potential to revolutionize cancer care worldwide,” said Charles Limoli, a professor of radiation oncology in UCI’s School of Medicine and co-author of the study, which appears online this week in Proceedings of the National…

UCI team helps uncover how ‘FLASH radiotherapy’ reduces neural cell damage   Irvine, Calif., May 13, 2019 — In hopeful news for brain cancer patients, researchers from the University of California, Irvine and the University of Lausanne in Switzerland have discovered how an experimental technology called FLASH radiotherapy dramatically reduces the adverse cognitive side effects unleashed by traditional radiation treatments.   “Although more research needs to be done, this has the potential to revolutionize cancer care worldwide,” said Charles Limoli, a professor of radiation oncology in UCI’s School of Medicine and co-author of the study, which appears online this week in Proceedings of the National…

Philadelphia, PA (May 3, 2019) – Oncoceutics, Inc. announced the publication of two scientific research articles demonstrating that members of the imipridone family ONC201 and ONC212 directly activate a mitochondrial protease called caseinolytic protease P (ClpP).One research article, featured on the cover of the journal Cancer Cell, demonstrates that ONC201 and ONC212 hyperactivate ClpP by altering its structural conformation, leading to mitochondrial dysfunction and apoptosis in leukemia. In AML, ClpP is over-expressed in patient samples and its hyperactivation selectively kills cancer cells independent of p53 status, while not affecting normal cells.Another research article, published in the journal ACS Chemical Biology, similarly demonstrates that ONC201…

Composition of Matter Patent and Translational Research Grant issued for ONC213Philadelphia, PA (April 30, 2019) – Oncoceutics, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued patent #10,266,533 entitled “7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-A]PYRIDO [3,4-E]PYRIMIDIN-5(1H)-ONE, ANALOGS THEREOF, AND SALTS THEREOF AND METHODS FOR THEIR USE IN THERAPY” with an expiration date of January 29, 2036. This patent covers the composition of matter for ONC213, its di-salt formulation, and its use in the treatment of cancer. In addition to the claims related to ONC213, the patent also contains claims for millions of structurally-related imipridones. ONC213 is the fourth molecule in the…

Greg Van Wyk Noxopharm Chief Medical Officer Discusses Veyonda In Depth, Enhancing Chemo & Radiotherapies.

Greg Van Wyk Noxopharm Chief Medical Officer Discusses Veyonda & Isoflavonoid Studies.

Greg Van Wyk Noxopharm Chief Medical Officer Discusses Veyondas Future In NSCLC, Sarcomas & Prostate Cancer.

Greg Van Wyk Noxopharm Chief Medical Officer Discusses Developing Isoflavone Idronoxil For Oncology Purposes.

Earn CME: https://naccme.com/program/7328 In this presentation from the ‘Updates on Treatment Approaches Across the Multiple Myeloma Spectrum’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Noopur Raje provides an update on the standard of care for maintenance therapy in patients with multiple myeloma. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7328 In this presentation from the ‘Updates on Treatment Approaches Across the Multiple Myeloma Spectrum’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Jonathan L. Kaufman provides an update on first line therapy for multiple myeloma. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7328 In this presentation from the ‘Updates on Treatment Approaches Across the Multiple Myeloma Spectrum’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Thomas G. Martin discusses emerging immunotherapies for the treatment of multiple myeloma. © 2019 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7328 In this presentation from the ‘Updates on Treatment Approaches Across the Multiple Myeloma Spectrum’ symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Saad Z. Usmani discusses recent advances in small molecule inhibition for the treatment of multiple myeloma. © 2019 Imedex, an HMP Company

Philadelphia, PA (April 24, 2019) – Oncoceutics announced today that Accelerate Brain Cancer Cure (ABC2) has awarded a $116,523 grant to a research team at University of California, Los Angeles to perform a natural disease history study of adult midline gliomas, a certain type of aggressive brain tumors. The study will follow patients from first diagnosis through a series of therapeutic interventions that for a subset of patients will include ONC201, an investigational agent in clinical trials for H3 K27M-mutant gliomas that has induced radiographic regressions in some patients.“Novel therapies are desperately needed for treatment of H3 K27M-mutant gliomas,” said…

test video spanish upload

Christopher Haqq M.D., PhD Executive Vise President Of Atara Biotherapeutics Discusses Engineering EBV Specific T cells.

Christopher Haqq M.D., PhD Executive Vise President Of Atara Biotherapeutics Discusses Mesothelin Targeted CAR-T Study.

Christopher Haqq M.D., PhD Executive Vise President Of Atara Biotherapeutics Discusses EBV CD19 CAR-T Cells Potency.

Christopher Haqq M.D., PhD Executive Vise President Of Atara Biotherapeutics Discusses Subset Of 11 Mesothelioma Patients.

NEW DATA SHOW BLUEPRINT® IDENTIFIES ESTROGEN RECEPTOR POSITIVE BREAST CANCER PATIENTS WITH POOR RESPONSE TO ANTI-ESTROGEN THERAPY WHO MAY BENEFIT FROM NEOADJUVANT CHEMOTHERAPY   ER+ breast cancer patients reclassified as ER+ basal-type demonstrated significant response to chemotherapy underscoring critical role of advanced diagnostic tools   Results published in Nature Publishing Group’s npj Breast Cancer   IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS –24 April, 2019 – Agendia, Inc., a world leader in precision oncology, today announced the publication of study results for BluePrint®, its 80-gene proprietary molecular subtyping test, in Nature Breast Cancer. It is well known that a significant subset of patients diagnosed with early stage, estrogen…

Scott Kopetz M.D., PhD., FACP Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Discusses

Scott Kopetz M.D., PhD., FACP Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Discusses Understanding Early Onset Colorectal Cancer.

Scott Kopetz M.D., PhD., FACP Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Discusses Molecular Signatures In Colorectal Cancer.

Scott Kopetz M.D., PhD., FACP Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Discusses Increasing Incidences In Colorectal Cancer.

Vishwas Paralkar PhD, Cybrexa Chief Scientific Officer Discusses Combining Alphalex Technology With Rucaparib.

Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses What IRAK4 Degredation Offers.

Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses The Future Of The IRAK4 Degrader.

Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses Protein Degradation Technology.

Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses Elaborating On The IRAK4 Protein Degrader

Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses E3 Ligase Atlas In Development.

Toni Choueiri M.D. Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute/Brigham and Womens Hospital and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School Discusses Novel Oral HIF-2 Alpha Inhibitor PT2977. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.

Toni Choueiri M.D. Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute/Brigham and Womens Hospital and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School Discusses mTOR & PI3 Kinase Inhibitor Study. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.

Toni Choueiri M.D. Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute/Brigham and Womens Hospital and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School Discusses Elaborating On Frontline Therapies. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.

David Quinn M.D., PhD Associate Professor of Medicine (Clinical Scholar);Section Head, Genitourinary (GU) Oncology, Division of Cancer Medicine and Blood Diseases in the Department of Medicine At The Keck School Of Medicine Talks About Remembering Martin Gore. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.

David Quinn M.D., PhD Associate Professor of Medicine (Clinical Scholar);Section Head, Genitourinary (GU) Oncology, Division of Cancer Medicine and Blood Diseases in the Department of Medicine At The Keck School Of Medicine Discusses Debate On Cytoreductive Nephrectomy. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.

Jose Karam M.D., FACS Associate Professor in the Department of Urology at The University of Texas MD Anderson Cancer Center in Houston, Texas Discusses Neoadjuvant Trials In Kidney Cancer. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.

Laurence Albiges M.D., PhD medical oncologist in the Genitourinary group of the Department of Cancer Medicine at the Institute Gustave Roussy Discusses Treating Brain Metastases From RCC With Nivolumab. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.

Laurence Albiges M.D., PhD medical oncologist in the Genitourinary group of the Department of Cancer Medicine at the Institute Gustave Roussy Discusses Is HIF Inhibition The Right Target In RCC. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.

Axel Bex M.D. Department of Urology The Netherlands Cancer Institute Amsterdam Discusses Surgical Consequences Of Pretreating Patients With RCC. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.

Axel Bex M.D. Department of Urology The Netherlands Cancer Institute Amsterdam Discusses Surgery Or Therapy First. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.

Axel Bex M.D. Department of Urology The Netherlands Cancer Institute Amsterdam Discusses Elaborating On The CARMENA Trial. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.

Axel Bex M.D. Department of Urology The Netherlands Cancer Institute Amsterdam Discusses Perioperative Therapy In The CARMENA & PROBE Trials. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019.

We are pleased to share with you the videos from the live webcast. In this 5th video, the panel opens up for a Q&A session. For more we invite you to visit https://cancerGRACE.org

We are pleased to share with you the videos from the live webcast. In this 4th video, Dr. H. Jack West discusses “Systemic Therapies for Advanced NSCLC”. For more we invite you to visit https://cancerGRACE.org

We are pleased to share with you the videos from the live webcast. In this 3rd video, Dr. Eric Vallieres discusses “The Growing Potential Utility of Surgery in Advanced NSCLC”. For more we invite you to visit https://cancerGRACE.org

We are pleased to share with you the videos from the live webcast. In this 2nd video, Dr. Puneeth Iyengar discusses “Novel Indications for Local Therapy in Advanced NSCLC”.

We are pleased to share with you the videos from the live webcast. In this first video, Dr. West introduces the program and shares the floor with Dr. Vivek Mehta who discusses “Newer Technologies in Radiation”.

Grant Stewart PhD an academic surgeon at the University of Cambridge Discusses Why One Year Of Treatment With Dosing Of Drugs. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019

Grant Stewart PhD an academic surgeon at the University of Cambridge Discusses Elaborating On Multiple Kidney Cancer Studies. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019

Grant Stewart PhD an academic surgeon at the University of Cambridge Discusses Two IO Plus TKI Studies In Kidney Cancer. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019

Alessandro Volpe M.D. of the University of Eastern Piedmont Hospital, Maggiore Della Carita Hospital, Novara, Italy Discusses Treating Renal Masses with Minimal Invasive Ablative Technique. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019

Alessandro Volpe M.D. of the University of Eastern Piedmont Hospital, Maggiore Della Carita Hospital, Novara, Italy Discusses Criteria To Indicate Delayed Intervention After Inductive Surveillance. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019

Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses When Can cfDNA Profiling Be Applicable. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019

Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses Understanding Biology With ADAPTeR Study. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019

Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses Sensitivity Of cfDNA Method. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019

Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses Immune Signatures & Positioning Biopsy Needle. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019

Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses The ADAPTeR Study. At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019

Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses Elaborating On Cell-Free DNA (cfDNA). At The Fourteenth European International Kidney Cancer Symposium on Mar 29, 2019

Dr. Ash Tewari discusses the concept of race vs. genetics in Health Disparity research and treatment

Philadelphia, PA (April 9, 2019) –  Oncoceutics announced today the publication of an article entitled “First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M–mutant pediatric diffuse intrinsic pontine glioma: a case report” in the Journal of Neurosurgery (authored by Matthew D. Hall, M.D., MBA). The article summarizes the medical history of a 10-year-old girl with a diffuse intrinsic pontine glioma (DIPG) brain tumor. Following radiation therapy and treatment with ONC201 on a compassionate use basis, she developed near complete resolution of her presenting neurological symptoms for almost one year, enabling her return to school and participation in many normal activities.DIPG is a…

Earn CME credit: https://www.naccme.com/program/2018-i7956-1 PARP inhibitors are the most commonly used targeted therapy for patients with recurrent ovarian cancer, and the indications for the use of these drugs have expanded in recent months. This roundtable discussion between Dr. Robert L. Coleman and pharmacy experts in PARP treatment for ovarian cancer is specifically designed for health-system pharmacists, including specialty pharmacists, clinical pharmacists, oncology pharmacists, and other pharmacists involved in the management of patients with ovarian cancer. © 2018 Imedex, an HMP Company

Dr. Ben Levy discusses two trials that are trying to determine if Immunotherapy can help lung cancer patients with earlier stage disease. Click here for information about the PACIFIC trial. The lung cancer vaccine trial will begin in early 2016.

Drs. Ben Solomon, Leora Horn, & Jack West consider how valuable testing for PD-L1 expression is in clinical practice and whether it should be integrated in clinical decision making around immunotherapies.

Immune checkpoint inhibitors are now becoming approved and commercially available for patients with previously treated advanced NSCLC. Dr. Eddie Garon, medical oncologist at UCLA, summarizes key data and explains their current role in treatment.

Drs. Leora Horn, Ben Solomon, & Jack West consider the factors that might lead us to favor testing for PD-L1 at initial workup of a patient with advanced NSCLC or after progression.

Dr. Eddie Garon, UCLA, reviews the controversial question of whether PD-L1 expression is a reliable enough biomarker to be used to select patients to receive or not receive immune checkpoint inhibitor therapy in lung cancer.

Earn CME Credit: https://www.naccme.com/program/7327 Knowledge is evolving regarding numerous clinical aspects of immune thrombocytopenic purpura (ITP), and there remains significant variability in clinical practice patterns for its management. This activity features Drs. David P. Steensma and Ilene C. Weitz sharing their insights about data recently released in publication form pertaining to pharmacotherapy for ITP, with a focus on the use of thrombopoietin (TPO) receptor agonists. © 2019 Imedex, an HMP Company

Drs. Leora Horn, Ben Solomon, & Jack West assess whether clinical factors such as being a never-smoker or having a driver mutation (EGFR, ALK, etc.) reliably predict minimal benefit from immunotherapy agents.

Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.

Drs. Leora Horn, Ben Solomon, & Jack West review the potential rationale and possible limitations of combining different immuntherapy strategies with one another.

Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.

Drs. Ben Solomon, Leora Horn, & Jack West consider whether immunotherapy might prove to be more problematic when given to a broader population of older and frail patients with advanced lung cancer.

Drs. Leora Horn, Ben Solomon, & Jack West consider whether the data suggest that the better tested PD1 and PD-L1 inhibitors have differences in activity or tolerability or are essentially interchangeable.

Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the completion of a $105 million Series B financing led by Varian and new investor OrbiMed. Additional investors participating in the round are Perceptive Advisors, Pivotal bioVenture Partners, and Rock Springs Capital, along with the existing group of leading international investors, that include HealthCap, Adams Street Partners, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), TPG Biotech, Seroba Life Sciences, Genesys Capital, and FACIT. In conjunction with the new financing, Deepak Khuntia, Senior Vice President (SVP) and Chief Medical Officer (CMO) at Varian, Chau Q. Khuong, Partner at OrbiMed, and Heather Preston, Managing Director at Pivotal bioVenture Partners, will…

SOUTH SAN FRANCISCO, Calif., April 2, 2019 /PRNewswire/ – ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on the discovery and development of novel therapies against treatment-resistant cancers, today presented new preclinical data on its lead program ORIC-101, a selective and potent glucocorticoid receptor (GR) antagonist, at the American Association of Cancer Research (AACR) Annual Meeting in Atlanta, GA. The data were presented in a poster “ORIC-101 Reverses a GR-Driven EMT-like Phenotype and Sensitizes TNBC Cells to Chemotherapy (Abstract #3822)” during the Experimental and Molecular Therapeutics poster session. The Company’s research findings provide insight into the molecular basis of GR-mediated…

April 02, 2019 08:00 ET | Source: Cybrexa Therapeutics     Tumor-selective CBX-11 allows full dose co-administration with chemotherapy, enabling synergistic efficacy in HRD negative tumors   Poster presentation today during AACR Annual Meeting 2019 NEW HAVEN, Conn., April 02, 2019 (GLOBE NEWSWIRE) — Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalexâ„¢ tumor targeting platform, today announced that the FDA- and EMA-approved poly ADP-ribose polymerase (PARP) inhibitor rucaparib (marketed as Rubraca®) is conjugated in lead candidate CBX-11 (alphalexâ„¢-rucaparib). The first set of preclinical data supporting CBX-11 demonstrate that Cybrexa’s proprietary alphalexâ„¢ platform can enable full dose administration…

Drs. Ben Solomon, Leora Horn, & Jack West assess the utility and limitations of “liquid biopsies”, serum-based testing for molecular marker testing in lung cancer.

Dr. Jack West summarizes the rationale for testing immune checkpoint inhibitors as a first line treatment for patients with advanced NSCLC and highlights details of two trials testing this question.

Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation, focusing on a clinical trial with the novel hypoxia-induced pan-HER inhibitor TH4000.

Dr. Seema Nagpal insists on one thing from her lung cancer patients: Proof that they are enjoying their lives. November is Lung Cancer Awareness Month. What are you grateful for?

Daniel Goldstein MD Tel Aviv University discusses Moving from Observational Pharmacoeconomics to Interventional Pharmacoeconomics at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Cristina Suárez MD PhD Hospital Universitari Vall d´Hebron-Vall d´Hebron Institute of Oncology discusses SPAIN: SOGUG MODEL at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Tim OBrien Vice President of BAUS discusses Centralization of Nephrectomy in the UK The good the bad and the ugly at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Toni K. Choueiri, MD Director, The Lank Center for Genitourinary Oncology Dana-Farber Cancer Institute discusses The Combination of Avelumab + Axitinib (Ave/Axi) in Advanced RCC: a legitimate 1st line contender at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Ronan FlippotMD MSc discusses Brain Metastases in Renal Cell CarcinomaAre immune checkpoint inhibitors up to the task? discusses Brain Metastases in Renal Cell CarcinomaAre immune checkpoint inhibitors up to the task? at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Raquel Perez-Lopez Vall dHebron Institute of Oncology (VHIO)Principal Investigator-Radiomics Group discusses Recist vs iRecist: Clinically Significant? at the Kidney Cancer Association International Symposium 2019 at Dubrovnik, Croatia         recist vs irecist, kidney cancer association international symposium 2019, clinically significant

Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant Lymphoma at Late-Breaking Session of the American Association for Cancer Research Annual Meeting Cambridge, Mass. (March 29, 2019) – Kymera Therapeutics Inc., a biotechnology company pioneeringtargeted protein degradation to create breakthrough medicines for patients, will present new preclinical data for its first-in-class oral IRAK4 protein degrader, KYM-001, in MYD88-mutant lymphoma. Data will be presented in a late-breaking research session at the American Association for Cancer ResearchAnnual Meeting on April 3 from 8 a.m. – 12 p.m. (Poster #18, Session: Experimental and Molecular Therapeutics 2). The…

Frede Donskov, M.D., DMSc Professor of Oncology Chairman, Kidney Cancer Expert Committee, Danish Medicines Council Aarhus University Hospital Denmark discusses the Nordic Registry Approach at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Brian i. Rini, MD Cleveland Clinic discusses Axi/Pembro is the Standard of Care in mRCC at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Samra Turajlic The Royal Marsden NHS Foundation Trust, London, UK discusses the second part of A phase II study of Anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell cancer (ADAPTeR) at the Kidney Cancer International Symposium 2019 in Dubrovnik, Croatia

Dr Pablo Maroto Hospital Sant Pau Barcelona discusses New Network Around Oncologists at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Jean-Marie Michot, MD Drug Development Department Gustave Roussy, France jean-marie.michot@gustaveroussy.fr discusses IO toxicities in Kidney Cancer at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Jose A. Karam, MD, FACS Associate Professor Departments of Urology and Translational Molecular Pathology discusses  Update in IO Neoadjuvant (Preoperative) Trials at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Cristina Suárez MD PhD Hospital Universitari Vall d´Hebron-Vall d´Hebron Institute of Oncology discusses NEW TARGETS IN RCC:NKTR at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Brian Shuch, MD Associate Professor of Urology Director, UCLA Kidney Cancer Program Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research discusses Targeting RCC Metabolism: Glutaminase Inhibition at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Monika Wolkers, PhD m.wolkers@sanquin.nl discusses TIL products from Renal Cell Carcinomas are tumor-specific but poor cytokine producers at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Bernadett Szabados of Barts Cancer Institute discusses NEW TARGETS IN RCC at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Dr. Ross Camidge discusses a clinical trial studying patients with advanced stage lung cancer to identify those who may respond to a drug called ponatinib. Both small cell and non small cell lung cancer patients may be eligible.

Dr. Jack West reviews the concept of epigenetics, epigenetic priming, and whether oral azacytidine can improve outcomes in patients who receive immunotherapy for advanced lung cancer.

On this Thanksgiving Day, we salute lung cancer patient Jason Karg and his wife Kristyl for reminding us of the important things in life.

Dr. Ross Camidge talks about a clinical trial that will test to see if the drug tesevatinib will work to kill cancer that has progressed in the brains of EGFR-mutant lung cancer patients. The trial is scheduled to begin in late 2015 or early 2016.

Dr. Jack West reviews the Lung Cancer Master Protocol for second line treatment of patients with advanced squamous NSCLC, an “umbrella protocol” in which all patients undergo molecular testing and have treatment assigned by the results.

Gratitude is one of the most medicinal emotions we can feel. (Sara Avant Stover) Thank you for joining GRACE in our #LCAM15 activities.

As we learn more about immunotherapy for lung cancer, combinations with multiple immunotherapy agents are being explored. Medical oncologist Dr. Eddie Garon considers whether combinations are likely to emerge as the leading immunotherapy approach.

Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.

Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences among the first and second generation EGFR TKIs (Iressa, Tarceva, Gilotrif/Giotrif).

Drs. Ben Solomon, Leora Horn, & Jack West consider the range of treatment options for patients with an EGFR mutation and acquired resistance that does not harbor a T790M mutation.

W. Kimryn Rathmell, MD, PhD of Vanderbilt Ingram Cancer Center discusses Novel epigenetic targeting approaches at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Laurence Albiges, Gustave Roussy Villejuif, France discusses HIF-2aa new target in metastatic RCCat the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Toni K. Choueiri MD of Dana Farber discusses Randomised phase 2 study of sapanisertib (TAK?228/MLN0128) ± TAK-117 versus everolimus in patients with VEGF-targeted therapy-refractory metastatic clear cell renal cell carcinoma at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Philip Zeuschner, MD of Universität des Saarlandes, Saarbrücken (UKS) discusses Learning curves in 500 robot-assisted partial nephrectomies: the bed-side assistant counts at the Kidney Cancer Associations International Symposium 2019 in Dubrovnik, Croatia

Toni K. Choueiri, MD of Dana-Farber Cancer Institute, Boston, MA discusses A First-in-Human Phase 1/2 Trial of the Oral HIF-2a Inhibitor PT2977 in Patients with Advanced RCCat the Kidney Cancer Association International Symposium in Dubrovnik, Croatia

Prof. Alessandro VOLPE University of Eastern Piedmont Maggiore della Carità Hospital, Novara, Italy discusses SMALL RENAL MASSES NON SURGICAL MANAGEMENT at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Manuela Schmidinger, MD, Camillo Porta, MD, Romano Danesi, MD, PhD, Brian I. Rini, MD discuss Optimising advanced RCC treatment: the place of Fotivda®?(tivozanib) in 2019 and beyond at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Dr Emmanuel MEYER Department of radiation oncology Centre Fran̤ois Baclesse Caen РFrance discusses Oligometastatic disease: Localized vs systemic therapy Non-surgical local management of RCC at the Kidney Cancer Associations International Symposium 2019 in Dubrovnik, Croatia

Fernando Gómez Muñoz. MD PhD Vascular and Interventional Radiology Hospital Clinic de Barcelona Hospital Sant Joan de Deu, Barcelona Netherlands Kanker Instituut, Amsterdam dicusses Ablative Therapies Versus Surgery: How the Evidence May Be Improved? at the Kidney Cancer Association International Symposium

Stereotactic Ablative Body RadioTherapy in Kidney Cancer Ben Vanneste, MD, PhD Radiation-Oncologist, MAASTRO Clinic, The Netherlands discusses Stereotactic Ablative Body RadioTherapy in Kidney Cancer at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Dr Kevin Litchfield Kevin.litchfield@crick.ac.uk Twitter: @kevlitchfield discusses Genomic and Transcriptomic Biomarkers of IO Response in RCC at the Kidney Cancer International Symposium 2019 in Dubrovnik, Croatia

Grant D Stewart, MD Surgical Oncology Lead, University Lecturer, University of Cambridge Consultant Urological Surgeon, Addenbrookes Hospital discusses Adjuvant immuno-oncology trials update at the Kidney Cancer International Symposium 2019 in Dubrovnik, Croatia

Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.

Drs. Ben Solomon, Leora Horn, & Jack West evaluate the merits of broad genetic testing with a “next generation sequencing” platform compared to selective, limited testing for the most proven driver mutations in patients with advanced NSCLC.

Drs. Ben Solomon, Leora Horn, & Jack West evaluate the evidence and consider whether there are clinically significant differences among the second generation ALK inhibitors that would lead to a reason to prefer one over another for a particular patient.

Drs. Leora Horn, Ben Solomon, & Jack West review whether there are specific factors that should make one second generation ALK inhibitor more ideal than other competing options for a specific patient with an ALK rearrangement.

Dr. Taofeek Owonikoko reviews why we often see brain metastases develop as a first or only site of progression in patients with NSCLC and a driver mutation.

Dr. Karen Reckamp of City of Hope Cancer Center reviews the concept of acquired resistance to targeted therapies in patients with a driver mutation and why it occurs.

Dr. Eddie Garon reviews the pattern of response to immunotherapy in lung cancer, along with the concept of “pseudoprogression”.

Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active in acquired resistance and consider whether there are significant differences between them.

Drs. Ben Solomon, Leora Horn, & Jack West discuss whether the data highlighting cognitive deficits from whole brain radiation therapy (WBRT) for patients with brain metastases should change our recommendations for prophylactic cranial irradiation (PCI).

Drs. Ben Solomon, Leora Horn, & Jack West review impressive data demonstrating a striking survival improvement from successful efforts at smoking cessation among smokers undergoing lung cancer CT screening.

Dr. West moderates a question & answer session with Drs. Karen Reckamp and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.

James Larkin of the The Royal Marsden NHS Foundation Trust pays tribute to his friend and legendary oncologist Martin Gore at the Kidney Cancer International Symposium 2019 in Dubrovnik, Croatia

Thomas Powles Director of Barts Cancer Center. Professor of Urology Cancer, Barts Cancer Institute discusses firist line clear cell RCC: All change at the Kidney Cancer International Symposium 2019 in Dubrovnik, Croatia

W. Kimryn Rathmell, MD, PhD Director of the Division of Hematology and Oncology Vanderbilt University Medical Center discusses Endogenous retrovirus and immune response in RCC at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Samra Turajlic, MD The Royal Marsden NHS Foundation Trust outlines Cell-free tumour DNA (cfDNA) detection in advanced renal cell carcinoma at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Christopher Wood, MD MD Anderson Cancer Center expresses his thoughts on the late Martin Gore at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

David Quinn, MD USC Norris Comprehensive Cancer Center gives a heartfelt tribute to Dr. Martin Gore and his US/International Perspective at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Bernard Escudier of the Institut Gustave Roussy in Villejuif, France reminisces about his late friend Martin Gore at the Kidney Cancer Association International Symposium 2019 in Dubrovnik, Croatia

Tobias Klatte, MD, PhD, FEBU, FRCS(Ed) Consultant Urological Surgeon, Royal Bournemouth Hospital Visiting Researcher, University of Cambridge Honorary Lecturer, University of Edinburgh asks the question “Molecular biomarker for cytoreductive nephrectomy?” at the Kidney Cancer International Symposium 2019 in Dubrovnik, Croatia

This presentation aims to provide an overview of the mRCC patient journey and the challenges clinicians face. To explore how clinical decisions are taken today and the factors that affect our current choices. To examine the emerging role of IO combinations in mRCC management, and discuss our future patient selection dilemmas and unanswered questions. From the Kidney Cancer Association International Symposium 2019 in Dubrovnik

John B. Haanen MD PhD Department of Medical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital asks the question “Do we need a new Carmena in the IO era?”at the Kidney Cancer Association International Symposium in Dubrovnick 2019.

Andy Thomas from Kidney Cancer Support Network discusses Cytoreductive Nephrectomy Patient Perspective at the Kidney Cancer Association International Symposium in Dubrovnik 2019

Oncoceutics Expands Patent Family to Include Composition of Matter for ONC206 in Europe  Philadelphia, PA (March 4, 2019) – Oncoceutics, Inc. announced that the European Patent Office (EPO) has issued EP 3,068,401 entitled “7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, Salts Thereof and Methods of Use” with an expiration date of September 12, 2034.  This patent covers the composition of matter for ONC206, its di-salt formulation, and its use in the treatment of cancer.  ONC206, a member of the imipridone family of anti-cancer small molecules, has demonstrated anti-cancer activity and safety in preclinical models and is planned to enter the clinic in 2019. These patents pave the path for…

Axel Bex Royal Free London NHS Foundation Trust, UCL Division of Surgical and Interventional Science, London, UK and The Netherlands Cancer Institute, Amsterdam, Netherlands discusses “No nephrectomy versus deferred nephrectomy” at the Kidney Cancer Association International Symposium in Dubrovnik 2019

Michael Staehler, M.D. Ph.D. Head Interdisciplinary Center on Renal Tumors Department of Urology University of Munich, Germany takes the PROCytoreductive Nephrectomy in Kidney Cancer at the Kidney Cancer Association International Symposium in Dubrovnik 2019

Lorenzo Marconi, MD, FEBU Coimbra, Portugal discusses Clinical Marker for Cytoreductive Nephrectomy? at the Kidney Cancer International Symposium in Dubrovnik 2019.

John B. Haanen MD PhD gives the Fitzpatrick Memorial Lecture entitled Do we need a new Carmena in the IO era?

Dr. Leora Horn of Vanderbilt University reviews the rapidly evolving issue and growing value of repeat biopsies, including plasma sampling as a “liquid biopsy” option, in the setting of acquired resistance to a driver mutation in advanced NSCLC.

Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center reviews the limited data that help clarify the probability of benefit from new immunotherapy agents among patients with advanced NSCLC and an identified driver mutation.

Dr. West moderates a question & answer session with Drs. Leora Horn and Greg Riely on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.

Xalkori (crizotinib) has had great success treating ALK positive lung cancer patients. The next generation of ALK inhibitors are also showing great promise. In this video, Dr. Leena Gandhi of Dana-Farber Cancer Institute talks about the research.

Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr. Owonikoko outlines these options for patients.

The brain is a common site of disease in patients with ALK+ lung cancer. In this video, Dr. Horn illustrates the line-up of ALK+ treatments and how they work breaking through the blood/brain barrier.

Janet Daily-Freeman moderates a question & answer session with Drs. Leora Horn and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for ALK+ and ROS1 patients.

There are sub-types within the sub-type of EGFR mutation positive lung cancer. In this presentation, Dr. Jack West discusses the different activating mutations within EGFR positive tumors and how they impact treatment.

Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In this video he details what should go into the decision to modify treatment for those patients.

Drs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers progress.

Following the news on March 19, 2019 that Merck KGaA and Pfizer have discontinued the ongoing Phase III JAVELIN Ovarian PARP 100 study for previously untreated advanced ovarian cancer, Paul Jeng, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on Talzenna (talazoparib) in ovarian cancer: “The combination of Bavencio and Talzenna has seen a steady erosion of its prospects in ovarian cancer since the JAVELIN Ovarian PARP 100 study was initiated less than a year ago. Merck & Co. and AstraZeneca’s Lynparza has widened its lead over other PARP inhibitors in ovarian cancer with an…

AUBURNDALE, Mass., March 21, 2019 /PRNewswire/ – Candel Therapeutics (a.k.a. Advantagene, Inc.) announced today the treatment of the first high grade glioma patients in a study of its Gene Mediated Cytotoxic Immunotherapy (GMCIâ„¢; aglatimagene besadenovec plus prodrug) in combination with the checkpoint inhibitor nivolumab and standard of care (SOC) surgery, radiation and temozolomide.  Extensive clinical and preclinical data suggests that GMCI and this combination can significantly improve clinical outcomes. This newest study, BrTK04, is being conducted in collaboration with the Adult Brain Tumor Consortium, composed of eleven of the top clinical institutions in the country, and Bristol-Myers Squibb, manufacturer of nivolumab (Opdivo®).  The study chair is Dr. Patrick Wen, Director, Center…

(Kanazawa, 21 March 2019) Researchers at Kanazawa University report in Nature Communications what causes some lung-cancer patients to have an intrinsic resistance to the drug osimertinib: AXL, a protein belonging to the class of receptor tyrosine kinases.  The combined application of osimertinib and an AXL inhibitor is shown to limit intrinsic resistance to the drug. For treating cancer, drugs based on molecules known as tyrosine kinase inhibitors are sometimes used.  One such tyrosine kinase inhibitor, called osimertinib, has been used to treat EGFR-mutated lung cancer with a certain degree of efficacy.  (EGFR refers to “epidermal growth factor receptor”, a protein…

March 11, 2019 07:37 PM Eastern Daylight Time   NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved TRAZIMERAâ„¢ (trastuzumab-qyyp), a biosimilar to Herceptin® (trastuzumab),1 for the treatment of human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.2   “This is an important milestone in the U.S. which both adds to our growing portfolio of oncology treatments and has the potential to improve access to cancer care,” said Andy Schmeltz, Global President, Pfizer Oncology. “We are proud to be able to…

On March 8, the FDA granted the accelerated approval of Roche’s programmed cell death protein 1 (PD-1) inhibitor Tecentriq in combination with Abraxane (protein-bound paclitaxel) for the treatment of locally advanced or metastatic triple-negative breast cancer (TNBC). Adam Pearson, PhD, Oncology and Hematology Analyst at GlobalData, a leading data and analytics company, offers his view on the FDA approval of Tecentriq for TNBC: “The emergence of Tecentriq as the first-in-class PD-1 inhibitor in breast cancer marks the first approval of an immuno-oncology drug in breast cancer and signifies the introduction of a new treatment strategy in a therapeutically elusive subset…

March 18, 2019 BOULDER, Colo., March 18, 2019 /PRNewswire/ — Array BioPharma Inc. (NASDAQ: ARRY) today announced that the National Comprehensive Cancer Network® (NCCN®) has updated their Clinical Practice Guidelines in Oncology for Colon and Rectal Cancer to include BRAFTOVI® in combination with MEKTOVI® and an anti-EGFR antibody as a Category 2a treatment for patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC), after failure of one or two prior lines of therapy for metastatic disease. The BRAFV600E mutation is associated with a poor prognosis compared to patients with CRC who do not carry the BRAF mutation, and currently there are no…

Philadelphia, PA (February 22, 2019) – Oncoceutics, Inc., announces the expansion of its diverse collaborations across the National Institutes of Health (NIH) involving its imipridone family of anti-cancer compounds.  ONC206 has been studied extensively for several years in models of central nervous system cancers, including high grade gliomas as evaluated by the laboratory of Mark Gilbert, MD, Chief of the Neuro-Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI). These studies convincingly demonstrate that ONC206 exerts significant therapeutic effects on preclinical models of brain cancers that are commonly recognized as incurable. The properties of ONC206 that include penetrance of the…

Read press release online: https://ir.moleculin.com/press-releases/detail/117/moleculin-files-with-fda-for-expedited-approval-pathway-for HOUSTON, TX- March 13, 2019 - Moleculin Biotech, Inc., (NASDAQ: MBRX)(“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that it has submitted a request for Fast Track Designation with the US Food and Drug Administration (FDA) for its drug, Annamycin, for the treatment of relapsed or refractory acute myeloid leukemia (AML). View Development Pipeline: https://www.moleculin.com/pipeline/ “Now that we have some traction in our clinical trials of Annamycin for the treatment of relapsed or refractory AML,” commented Walter Klemp, Moleculin’s Chairman and CEO, “we believe…

Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses Discussing PEDIGREE Study. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com…

Evan Yu, MD, Professor, Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Institute, Discusses Results From KEYNOTE 365 In mCRPC. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Evan Yu, MD, Professor, Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Institute, Discusses When Sipuleucel-T Should Be Used In Treatment Of mCRPC. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Evan Yu, MD, Professor, Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Institute, Discusses Combining Checkpoint Inhibitors In Metastatic Castration-Resistant Prostate Cancer. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Evan Yu, MD, Professor, Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Institute, Discusses Combination Pembrolizumab And Olaparib In mCRPC. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Sumit K. Subudhi, MD, PhD, Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Discusses When Sipuleucel-T Should Be Used In Treatment Of mCRPC. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Sumit K. Subudhi, MD, PhD, Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Discusses Combining Checkpoint Inhibitors In mCRPC. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Sumit K. Subudhi, MD, PhD, Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Discusses The Outcomes Of The KEYNOTE 365 Study. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Bridget F. Koontz, MD, Associate Professor of Radiation Oncology, Duke University School of Medicine, Discusses Moderate Hypofractionation & Ultra-Hypofractionation In Prostate Cancer. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Bridget F. Koontz, MD, Associate Professor of Radiation Oncology, Duke University School of Medicine, Discusses The Evolving Landscape Of Prostate Cancer. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Bridget F. Koontz, MD, Associate Professor of Radiation Oncology, Duke University School of Medicine, Discusses New Guidelines On Hypofractionated EBRT In Prostate Cancer. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Tomasz Beer, MD, Professor of Medicine, Division of Hematology/Medical Oncology, Oregon Health Sciences University, Discusses Recent Data Utilizing LuPSMA In Men With mCRPC. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Tomasz Beer, MD, Professor of Medicine, Division of Hematology/Medical Oncology, Oregon Health Sciences University, Discusses The ARAMIS Study In nmCRPC From GU 2019. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

William Oh, MD, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, Discusses The Evolving Treatment Landscape For Patients With nmCRPC. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

William Oh, MD, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, Discusses How PSA Is Valuable As A Biomarker In The Treatment Of Prostate Cancer. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

William Oh, MD, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, Discusses Data On Racial Differences In Response To Novel Prostate Cancer Therapies. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

William Oh, MD, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, Discusses Recent Data Examining LuPSMA In Men With mCRPC. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Mark T. Fleming, MD, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, Discusses The Implications Of The CHECKMATE 650 Study Presented At GU 2019. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Mark T. Fleming, MD, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, Discusses The LATITUDE Study In NDx-HR mCNPC. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Mark T. Fleming, MD, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, Discusses Aramis Study In Prostate Cancer. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Mark T. Fleming, MD, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, Discusses The ARCHES Trial In Metastatic Hormone-Sensitive Prostate Cancer. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses The Challenges Using Biomarkers For Treatment Selection In Bladder Cancer. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses The Role Of Checkpoint Inhibitors In Bladder Cancer. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses Molecular Characterization & Subtyping Data In Bladder Cancer. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses The Latest In Screening For High-Risk Asymptomatic Bladder Cancer. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses Outcomes Of KEYNOTE 057 In High-Risk Non-Muscle-Invasive Bladder Cancer. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses The Evolution Of ADT In Prostate Cancer. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses Impression Of KEYNOTE 365 In mCRPC. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses Impression Of KEYNOTE 365 In mCRPC. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses Combination Pembrolizumab And Olaparib In mCRPC. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses Combining Checkpoint Inhibitors In mCRPC. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses Combining Checkpoint Inhibitors In mCRPC. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Rana McKay, MD, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, Discusses Recent Data Examining Atezolizumab And Bevacizumab In nccRCC & sccRCC. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Rana McKay, MD, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, Discusses The Implications Of CHECKMATE 214 & KEYNOTE-426 Presented At GU 2019. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019.http://obroncology.com         CHECKMATE 214, KEYNOTE-426, CHECKMATE 214 & KEYNOTE-426, GU 2019, Genitourinary Cancers Symposium

Rana McKay, MD, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, Discusses Outcomes Of The KEYNOTE 426 Phase III Study In mRCC. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Rana McKay, MD, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, Discusses TIVO-3 Study In Highly Refractory Advanced RCC Patients. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Rana McKay, MD, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, Discusses How To Differentiate Between TKIs Available For Renal Cell Cancer Patients. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Rana McKay, MD, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, Discusses Next Steps When Treating mRCC Patients Who Receive I-O In The Front Line Space. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Michael Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, Discusses IO-TKI Combinations In Renal Cell Cancer. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Michael Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, Discusses How To Treat mRCC After Combination I-O In The 1st Line Setting. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Michael Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, Discusses Single Agent TKIs In The 1st Line Setting. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Michael Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, Discusses Intermediate/Poor & Favorable Risk RCC Patients. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Michael Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, Discusses KEYNOTE 426 Phase III Trial In Metastatic Renal Cell Carcinoma. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Andrew Armstrong, MD Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, Discusses Phase 2 STREAM Study In Pre-Metastatic Prostate Cancer. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Andrew Armstrong, MD Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, Discusses Opinion On Androgen Receptor Inhibitors. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Andrew Armstrong, MD Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, Discusses Overview Of The ARCHES Trial In mHSPC. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses The Outcomes Of KEYNOTE 426 Presented At GU 2019. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses How To Treat mRCC After Combination I-O In The 1st Line Setting. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses Intermediate/Poor And Favorable Risk RCC Patients. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses Predictive Biomarkers In Selecting Patient Populations For I-O Treatment In RCC. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Oncoceutics Licenses Rights to ONC201 for Japan to Ohara Pharmaceutical Co., Ltd. Philadelphia, PA (February 15, 2019) – Oncoceutics, Inc. announced today the outlicense of the rights to the company’s lead compound, ONC201, for Japan to Ohara Pharmaceutical Co., Ltd. In addition, Ohara will receive a right of first refusal on the license of ONC201 for additional areas, including most of Asia and West Africa, and a right of first refusal for the company’s next generation compound, ONC206, in these territories.  In return for the license and future rights, Ohara will make a multi-part payment to Oncoceutics including upfront payments, milestone payments,…

Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses Should Patients In The 1st Line Setting Should Receive A Single Agent TKI. At The 2019 Genitourinary Cancers Symposium In San Francisco, CA On Feb 14, 2019. http://obroncology.com

Laura S. Wood, R.N., MSN, OCN, Cleveland Clinic Discusses Aimwithimmunotherapy.org And The Various Resources The Site Provides For Patients And Physicians.

(WASHINGTON, March 12, 2019) — Yesterday, President Donald Trump released a fiscal year 2020 budget request that proposes a 12 percent cut to the U.S. Department of Health and Human Services (HHS). This includes a $4.716 billion (12.1%) cut to the National Institutes of Health (NIH), the nation’s largest funder of biomedical research, and a $750 million cut in funding to the Centers for Disease Control and Prevention (CDC). These agencies play a vital role in supporting much of the world’s hematology-related biomedical research and in supporting programs to prevent and control clotting, bleeding, and other hematologic disorders.  2019 American…

Wood LS, Hoffner B, Rubin K, Davies MJ, Tushla LA, Guild V, Guild SR. Background Immune checkpoint inhibitors (ICIs) have changed treatment options for many cancer patients. Educating HCPs, patients, caregivers is crucial to early identification of irAEs, ensuring prompt intervention and improved outcomes. Resources for oncology HCPs are scattered, including published articles, websites, and pharmaceutical materials. These resources are restricted to information from the package insert and limited in the scope of guidance provided. Methods Melanoma advance practice providers (APPs) collaborated with the AIM at Melanoma Foundation and Terranova Medica in 2016 to create the Melanoma Nurse Initiative, featuring…

Laura S. Wood, R.N., MSN, OCN, Cleveland Clinic Discusses Whats Next With Aimwithimmunotherapy.org. For More Info Visit: Aimwithimmunotherapy.org

Laura S. Wood, R.N., MSN, OCN, Cleveland Clinic Discusses Benefits Of Aimwithimmunotherapy.org And The Various Resources It Provides For Patients And Physicians. For More Info Visit: Aimwithimmunotherapy.org

Laura S. Wood, R.N., MSN, OCN, Cleveland Clinic Discusses Assessment & Education Regarding (irAEs). For More Info Visit: Aimwithimmunotherapy.org

Brendan Bietry of the Patient Advocate Foundation discusses the financial assistance programs available to lung cancer patients who receive targeted therapies.

Dr. Jack West, Brendan Bietry, and Janet Freeman-Daily take questions from the audience about financial assistance, legal protections, and patient support.

Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely to use these agents instead of or in combination with standard chemotherapy soon.

Dr. Julie Brahmer, Johns Hopkins University, discusses immunotherapies for NSCLC and SCLC, analyzes the relevant trial data and addresses the unique side effects of these therapies.

Dr. Ed Kim from the Levine Cancer Institute in Charlotte, NC summarizes the mechanism of next generation sequencing (NGS), how it can potentially be used, and its limitations in clinical practice today.